Entries by ginealach

Amphista Therapeutics Appoints Dr Martin Pass as CDO

Cambridge, England, 6 December 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Martin Pass, as Chief Development Officer (CDO). Martin joins Amphista from AstraZeneca, where he was Vice President, Head Early Oncology Projects and led successful clinical development efforts. Martin has over 30 […]

Amphista Therapeutics Appoints CBO, Beverley Carr

Cambridge, England, 1 November 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of a Chief Business Officer (CBO), Beverley Carr. Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team, I am thrilled to welcome Beverley as our CBO.  Beverley brings a wealth […]

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

Glasgow, UK, 21 September 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team I am thrilled to welcome someone of Josh’s calibre […]

Bio21

Bio21 14 June 2021 – 18 June 2021